Biogen Reports Top-Line Results from Phase 2b Study of Natalizumab in Acute Ischemic Stroke

Wednesday, February 7, 2018 1 min read

Key Takeaway: Biogen Reports Top-Line Results from Phase 2b Study of Natalizumab in Acute Ischemic Stroke

Full Press Release Details

Biogen Reports Top-Line Results from Phase 2b Study of Natalizumab in Acute Ischemic Stroke.